NCT04655222 is a clinical trial of Interferon Beta Therapy in Multiple Sclerosis, sponsored by Biogen.

Who is sponsoring NCT04655222?

NCT04655222 is sponsored by Biogen.

What drugs are being tested in NCT04655222?

Interventions in NCT04655222: Interferon Beta Therapy.

What condition does NCT04655222 study?

NCT04655222 studies Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting.

Is NCT04655222 still recruiting?

NCT04655222 is currently completed. Last updated 18 April 2023.

Last reviewed 2023-04-18 · How we verify

NCT04655222

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Completed Last updated 18 April 2023

What this trial tests

trial testing Interferon Beta Therapy in Multiple Sclerosis in 470 participants. Completed in 15 October 2021.

Timeline

30 April 2021

Primary endpoint
15 October 2021

15 October 2021

Quick facts

Lead sponsor	Biogen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	470
Start date	30 April 2021
Primary completion	15 October 2021
Estimated completion	15 October 2021
Sites	1 location across Germany

Drugs / interventions tested

Interferon Beta Therapy — full drug profile →

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →
Multiple Sclerosis, Relapsing-Remitting — all drugs for Multiple Sclerosis, Relapsing-Remitting →

Sponsor

Biogen — full company profile →

Who can join

18 and older, female only, with Multiple Sclerosis or Multiple Sclerosis, Relapsing-Remitting. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective(s) of the study is to evaluate the impact of exposure to SC Peginterferon beta-1a or IM Interferon beta-1a before and during pregnancy on pregnancy outcome in female participants who had registered in the German Patient Support Program (PSP) and of whom a pregnancy report and pregnancy outcome report is available. The secondary objectives of this study are applicable for a subpopulation of the above-mentioned population, i.e. for participants of whom data on a standardized questionnaire collected during a telephone interview is available.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Impact of interferon beta exposure on birth outcome and child development - Results from the post-authorisation safety study PRIMA.
Klehmet J, Begus-Nahrmann Y, Taipale K, Niemczyk G, et al · · 2023 · cited 5× · PMID 37393802 · DOI 10.1016/j.msard.2023.104844
Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme - results from the non-interventional post-authorization safety study PRIMA.
Klehmet J, Begus-Nahrmann Y, Taipale K, Niemczyk G, et al · · 2023 · PMID 38107443 · DOI 10.1177/17562864231214041

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other Biogen trials

Trials by the same sponsor.

NCT07483632 — A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses · Phase 3 · not yet recruiting
NCT06628687 — A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it Duri · recruiting
NCT07444450 — A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy · Phase 3 · not yet recruiting
NCT07444489 — A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants · Phase 3 · not yet recruiting
NCT07444476 — A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years Wit · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04655222 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biogen
Last refreshed: 18 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04655222.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing